Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
VzTetWfqwnQqrHtQ
